BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

## 15. Bharat Biotech

22 July 2013 | Features | By BioSpectrum Bureau

**15. Bharat Biotech**



**Rank 15**

**Betting on Rotoavac**

During the FY 2012-13, the Bharat Biotech registered an annual turnover of `299.83 crore as against `277.7 crore recorded in FY 2011-12. Though the company has displayed marginal growth during this fiscal year, it is banking upon new opportunities. It has invested a significant amount of money on conducting clinical trials of seven of its products. These products include therapeutics and vaccines that are at an advanced stage of development. It has product development projects in varying stages for the vaccines and therapeutics, such as malaria, rotavirus, typhoid, Japanese encephalitis, pandemic influenza, chikungunya, and staphylococcus aureus.

The company has developed a three-dimensional business model with emphasis on biogenerics, contract manufacturing and research, and novel products. This strategy has given Bharat Biotech the ability to earn revenues in the short and medium term while focusing on novel patent protected products for the long term. The company claims to have the largest manufacturing capacity for making hepatitis-B (10 crore doses), typhoid vaccine (five crore doses) and rabies (80 lakh doses).

Rotavac, the first oral rotavirus vaccine developed by Bharat Biotech has successfully completed the phase III clinical trials, being one of the first and largest phase III clinical trial in Indian history encompassing 10,000 infants. The company has invested `231.7 crore ($50 million) in the clinical trials, with funding assistance from Gates Foundation.and the Department of Biotechnology, Government of India. With the trials data reporting 60 percent efficacy and no significant side effects, the Bharat Biotech is set to approach the DCGI in July, 2013 for approval to produce the vaccine.

"Rotavac represents the successful research and development of a novel vaccine from the developing world with global standards," said Dr Krishna M Ella, chairman and managing director, Bharat Biotech. "It is a testament of our strong vision and commitment to develop affordable health care solutions for infectious diseases."

**Company:** Bharat Biotech
**Business:** Vaccines and Therepeutics
**Revenue:** 2013 `299.83 crore

Â